REGN
Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 74.11K | $47.57M | n/a | −4 |
| Q2 2026 | 167 | -1 | 75.04M | $46.86B | +5 | −7 |
| Q1 2026 | 172 | -4 | 77.87M | $60.04B | +2 | −7 |
| Q4 2025 | 175 | 0 | 81.03M | $62.54B | +1 | n/a |
| Q3 2025 | 27 | -1 | 48.96M | $27.52B | n/a | −2 |
| Q2 2025 | 26 | +2 | 40.24M | $21.12B | +3 | −1 |
| Q1 2025 | 21 | +1 | 16.62M | $10.53B | +1 | n/a |
| Q4 2024 | 20 | -1 | 17.24M | $12.28B | n/a | −1 |
| Q3 2024 | 20 | +1 | 13.10M | $13.76B | +2 | −1 |
| Q2 2024 | 19 | n/a | 13.77M | $14.47B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 4.64M | n/a | $4.88B | 0.8% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.42M | n/a | $2.53B | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 3 | Dodge & Cox ✦ | 2.32M | n/a | $2.43B | 1.5% | n/c | 1 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 1.13M | n/a | $1.18B | 0.2% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.06M | n/a | $1.12B | 0.2% | n/c | 1 | SEC ↗ ×8 |
| 6 | T. Rowe Price ✦ | 932.87K | n/a | $980.48M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 267.03K | n/a | $280.66M | 0.2% | n/c | 1 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 254.41K | n/a | $267.40M | 0.4% | n/c | 1 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 189.29K | n/a | $198.57M | 0.3% | n/c | 1 | SEC ↗ ×3 |
| 10 | Renaissance Technologies ✦ | 185.16K | n/a | $194.61M | 0.3% | n/c | 1 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 162.50K | n/a | $170.79M | 0.3% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 109.56K | n/a | $115.15M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 58.87K | n/a | $61.88M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 22.87K | n/a | $24.04M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | ARK Investment Management ✦ | 15.87K | n/a | $16.67M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 5.70K | n/a | $5.99M | 0.1% | n/c | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 5.67K | n/a | $5.95M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Bridgewater Associates ✦ | 5.35K | n/a | $5.63M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | GAMCO Investors ✦ | 307 | n/a | $322,666 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,385 holders, 83.52M shares, $61.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 50 sh · $39,074
Officer · 127 sh · $97,701
Officer · 12 sh · $9,242
Officer · 283 sh · $218,351
Officer · 211 sh · $163,010
Officer · 224 sh · $173,242
Officer · 121 sh · $93,712
Officer · 376 sh · $291,573
Officer · 66 sh · $51,236
Officer · 38 sh · $29,555
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology